{
    "clinical_study": {
        "@rank": "104323", 
        "arm_group": {
            "arm_group_label": "BMS-986016", 
            "arm_group_type": "Experimental", 
            "description": "Part A: Dose Escalation: BMS-986016 20,80,240, 800 mg solution intravenously every 2 weeks during each 8 week cycle, up to 12 cycles\nPart B: Dose Expansion: BMS-986016 dose selected from Part A solution intravenously every 2 weeks during each 8 week cycle, up to 12 cycles"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to characterize the safety, tolerability, dose limiting\n      toxicities and maximum tolerated dose of BMS-986016 administered to subjects with relapsed\n      or refractory chronic lymphocytic leukemia and lymphomas."
        }, 
        "brief_title": "Safety Study of Anti-LAG-3 in CLL, HL and NHL", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Hematologic Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Chronic Lymphocytic Leukemia (CLL)\n\n      Hodgkin Lymphoma (HL)\n\n      Non-Hodgkin Lymphoma (NHL)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Part A:\n\n               -  Chronic Lymphocytic Leukemia\n\n               -  Hodgkin Lymphoma\n\n               -  Non Hodgkin Lymphoma\n\n          -  Part B:\n\n               -  Chronic Lymphocytic Leukemia\n\n               -  Hodgkin Lymphoma\n\n               -  Diffuse Large B-cell Lymphoma\n\n               -  Mantle Cell Lymphoma\n\n          -  Progressed, or been refractory to at least one prior standard therapy, including\n             radiation, immunotherapy, cytotoxic chemotherapy, and select antibody (anti-CD20,\n             Alemtuzumab, or Brentuximab) therapy\n\n          -  Not eligible for or declined transplantation or any standard therapy known to be life\n             prolonging or life saving\n\n          -  Subjects without prior exposure to immune cell modulating antibody regimens such as\n             anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death\n             protein 1 (PD-1), anti-programmed cell death protein ligand 1 (PD-L1), anti-PD-L2,\n             anti-KIR, anti-CD137, or anti-OX40 antibodies.  Prior anti-CD20, Alemtuzumab or\n             Brentuximab antibody therapy is allowed\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  At least 1 lesion with measurable disease\n\n          -  Willing to consent to allow a pre-treatment bone marrow biopsy\n\n          -  Willing to consent to a pre-treatment tumor biopsy or allow the acquisition of an\n             existing tumor sample\n\n        Exclusion Criteria:\n\n          -  Primary cutaneous lymphoma, lymphoproliferative diseases associated with primary\n             immune deficiencies, and lymphomas associated with human immunodeficiency virus (HIV)\n             infection\n\n          -  Known or suspected central nervous system (CNS) metastases or with the CNS as the\n             only site of active disease (controlled CNS metastases are allowed)\n\n          -  Autoimmune disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061761", 
            "org_study_id": "CA224-022"
        }, 
        "intervention": {
            "arm_group_label": "BMS-986016", 
            "intervention_name": "BMS-986016", 
            "intervention_type": "Biological", 
            "other_name": "Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3)"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Site 0007"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21231"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Philippe Armand, Site 0004", 
                    "phone": "617-632-2368"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0003"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ajay Gopal, Site 0001", 
                    "phone": "206-288-2037"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Seattle Cancer Care Alliance"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety measured by the rate of Adverse events (AEs), Serious Adverse events (SAEs), death and laboratory abnormalities", 
            "safety_issue": "Yes", 
            "time_frame": "Up to approximately 2.3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061761"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum observed serum concentration (Cmax) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Time of maximum observed serum concentration (Tmax) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Trough observed serum concentration (Ctrough) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Concentration observed at the end of infusion (Ceoinf) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Concentration at the end of a dosing interval (Ctau) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Average concentration over a dosing interval [AUC(TAU)/tau] (Css,avg) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of followup (approximately 2.3 years)"
            }, 
            {
                "measure": "Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Total body clearance (CLT) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Volume of distribution at steady state (Vss) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Effective elimination half-life that explains the degree of AUC accumulation observed (T-HALFeff AUC) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Effective elimination half-life that explains the degree of Cmax accumulation observed (T-HALFeff Cmax) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Accumulation index; ration of AUC(TAU) at steady state to AUC(TAU) after the first dose (AI_AUC) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Cmax accumulation index; ratio of Cmax at steady state to Cmax after the first dose (AI_Cmax) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Ctau accumulation index; ratio of Ctau at steady state to Ctau after the first dose (AI_Ctau) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Ceoinf accumulation index; ratio of Ceoinf at steady state to Ceoinf after the first dose (AI_Ceoinf) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "measure": "Degree of fluctuation or fluctuation index ([Cmax - Ctau]/Css,avg) (DF) of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "24 timepoints up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "description": "Immunogenicity (ADA): The proportion of subjects who are anti-drug antibody (ADA)-positive at baseline, the proportion of subjects who become ADA-positive on study, and the proportion of subjects who remain ADA-negative to BMS-986016", 
                "measure": "Immunogenicity of BMS-986016", 
                "safety_issue": "No", 
                "time_frame": "Up to 135 day of follow-up (approximately 2.3 years)"
            }, 
            {
                "description": "ORR is the proportion of subjects with a best overall response of Complete Response (CR) or Partial Response (PR)", 
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1.9 years"
            }, 
            {
                "description": "DOR based on current criteria relevant to each disease type", 
                "measure": "Duration of response (DOR)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1.9 years"
            }, 
            {
                "measure": "Landmark progression-free survival rate (PFSR)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 1.9 years"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}